L'intérêt à découvert pour F&G Annuities & Life donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de F&G Annuities & Life. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

F&G Annuities & Life (NYSE:FG) Stock, Rapport sur les intérêts à découvert

F&G Annuities & Life

F&G Annuities & Life Inc is a provider of insurance solutions serving retail annuity and life customers as well as institutional clients. Through its insurance subsidiaries, including FGL Insurance and Fidelity & Guaranty Life Insurance Company of New York it markets a broad portfolio of deferred annuities (fixed indexed annuities (FIAs) and multi-year guarantee annuities (MYGAs) or other fixed rate annuities), immediate annuities, indexed universal life (IUL) insurance, funding agreements through funding agreement-backed notes (FABN) issuances and the Federal Home Loan Bank of Atlanta (FHLB)), and pension risk transfer (PRT) solutions.

F&G Annuities & Life Inc

FASTIGHETS AKTIEBLAET AKB by FASTIGHETS AKTIEBOLAGET

First Trust Specialty Finance and Financial Opportunities Fund

First Trust Specialty Fnc & Fncl Oppor

FIRST GLOBAL DATA LTD by First Global Data Ltd.

First Guaranty Bancshares, Inc. - Common Stock

First Guaranty Bancshares Inc

First Guaranty Bancshares, Inc. - 6.75% Series A Fixed-Rate Non-Cumulative Perpetual Preferred Stock

FLAGSHIP GLOBAL CORP by Flagship Global Corporation

FINANCIAL GRAVITY COMP by Financial Gravity Companies, Inc.

Financial Gravity Companies Inc

First Trust DJ Global Select Dividend

Franklin Templeton Holdings Trust Franklin Responsibly Sourced Gold ETF

First General Bank

FUJITSU GENERAL LTD ORD by Fujitsu General Ltd.

Fujitsu General Ltd

FibroGen Inc

FLIGHT CENTRE TRAVEL GRP by FLIGHT CENTRE TRAVEL GROUP LTD

Flight Centre Travel Group Ltd

Fundamental Global Inc

FORESIGHT FINCL GRP INC by Foresight Financial Group Inc.

Foresight Financial Group

FIRST GREENWICH FCL INC by First Greenwich Financial Inc.

First Greenwich Financial Inc

Fundamental Global Inc. - 8.00% Cumulative Series A Preferred Stock

FG FITNESS & MED GRP INC by FG Fitness & Media Group, Inc.

FG Fitness & Media Group Inc

FG GROUP HLDGS INC COM

FORTE GROUP HLDGS INC by FORTE GROUP HLDGS INC.

Forte Group Holdings Inc

FRONTAGE HLDGS CORP by Frontage Hldgs Corp.

Frontage Holdings Corp

FLIGHT CEN TRAVEL UN/ADR by FLIGHT CENTRE TRAVEL GROUP LTD

FGI Industries Ltd

Founder Group Ltd

Falcon Gold Corp

First Trust Germany AlphaDEX Fund

FG Merger II Corp

FG Merger II Corp. - Rights

F&G Annuities & Life, Inc. 7.950% Senior Notes due 2053

FORGE INNOVATION DEV CORP by Forge Innovation Dev Corp.

Forge Innovation Development Corp

FREEGOLD VENTURES LTD by Freegold Ventures Ltd.

Freegold Ventures Ltd

FIRST GRAPHENE LTD by First Graphene Limited

First Graphene Ltd

Ferrellgas Partners LP

FirstGroup PLC

FIRSTGROUP PLC UNSP/ADR by Firstgroup PLC

FINGERPRINT CARD AB ORD B by Fingerprint Cards AB

Fingerprint Cards AB

FingerTango Inc

FLAT GLASS GRP BRER SHS H by FLAT GLASS GROUP CO LTD.

Flat Glass Group Co Ltd

The Advisors' Inner Circle Fund II Frontier Asset Global Small Cap Equity ETF

F&G Annuities & Life, Inc. 7.300% Junior Subordinated Notes due 2065

FLUGHAFEN WIEN AG ORD NEW by Flughafen Wien AG

Flughafen Wien AG

WIIM

ADAP

Adaptimmune Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCX#NASDAQ">OCX</a>) with a Buy and maintains $4.25 price target.

News

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on OncoCyte, Maintains $4.25 Price Target

Earnings

Earnings Beats

Earnings Misses

LSTR

Landstar System Q1 EPS $0.85 Misses $0.99 Estimate, Sales $1.15B Beat $1.13B Estimate

SGMO

Sangamo Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.

Bridgemarq Real Estate (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BRE#TSX">BRE</a>) reported quarterly earnings of $0.20 per share. This is a 5.26 percent increase over earnings of $0.19 per share from the same period last year. The company reported $77.97 million in sales this quarter. This is a 562.62 percent increase over sales of $11.77 million the same period last year.

TSX:BRE

Bridgemarq Real Estate Q1 Adj. EPS $0.20 Up From $0.19 YoY, Sales $77.97M Up From $11.77M YoY

ITOS

Trading Halt: Halted at 7:50:00 a.m. ET - Trading Halt: Halt News Pending

Palmer Luckey, the virtual-reality prodigy who sold Oculus to Facebook for $2 billion in 2014, says that payday granted him entry to an ultra-exclusive group chat called the "B Boys Club."
What Happened: The only password to the group chat is a unicorn-level exit: founders must have sold a company for at least $1 billion. "It's all boys who have sold a company for at least $1 billion," Luckey <a href="https://www.youtube.com/watch?v=21I_3VEs0iI">told</a> Peter Diamandis on the "Moonshots" podcast. While he insists women aren't barred, none are in the thread.
That omission is striking given deals like L'Oréal's $1.2 billion purchase of IT Cosmetics from co-founder Jamie Kern Lima in 2016.
By club standards, Instagram's Kevin Systrom and Mike Krieger (<a href="https://www.benzinga.com/news/15/10/5891968/instagrams-fifth-anniversary-how-good-of-a-deal-was-this-for-facebook">sold</a> to Facebook for $1 billion in 2012) would qualify easily. So would WhatsApp's Jan Koum and Brian Acton, who <a href="https://www.benzinga.com/news/14/02/4322191/update-facebook-announces-16b-cash-stock-merger-with-whatsapp">fetched</a> $19 billion two years later. Slack co-founder Stewart Butterfield dwarfs them all, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/20/12/18616683/6-salesforce-analysts-react-to-slack-deal-game-changer-potential">exiting</a> to Salesforce for $27.7 billion in 2021.
See also: <a href="https://www.benzinga.com/25/05/45370909/china-rejects-us-blame-for-fentanyl-crisis-calls-tariff-penalties-unreasonable-amid-easing-trade-tensions">China Rejects US Blame For Fentanyl Crisis, Calls Tariff Penalties Unreasonable Amid Easing Trade Tensions</a>
Some of the planet's richest men, however, are stuck on read. Meta chief Mark Zuckerberg, who&#8217;s worth roughly $226 billion by Bloomberg's latest count, never actually sold Facebook, so he's out, as are Bill Gates, Sam Altman and Warren Buffett.
What To Know: Luckey, now <a href="https://www.forbes.com/profile/palmer-luckey/">valued</a> by Forbes at about $2.5 billion thanks to defense-tech startup Anduril, spends his chat time "shaming" peers into using their fortunes for more than vintage race cars.
"Guys, you have so much money. Why are you not doing what you know is the right thing to do with this capital?" he recalled messaging.
Luckey believes founders should personally build the world they envision instead of outsourcing philanthropy. Some converts are redirecting cash; others, he concedes, still prefer the fast lane. "I'm not saying everyone should become a vigilante crime fighter, but why wouldn't you use your resources to do the thing that you know needs to be done?" Luckey said.
Image via Just dance/Shutterstock
Read next: <a href="https://www.benzinga.com/news/global/25/05/45369837/piers-morgan-tears-into-pakistani-expert-who-says-isi-didnt-know-osama-bin-laden-was-living-near-military-base-all-they-had-to-do-was-get-a-pair-of-binoculars">Piers Morgan Tears Into Pakistani Expert Who Says ISI &#8216;Didn&#8217;t Know&#8217; Osama Bin Laden Was Living Near Military Base: &#8216;All They Had To Do Was Get A Pair Of Binoculars&#8217;</a>

Tech

Oculus Founder Palmer Luckey Reveals He's In An Invite-Only Group Chat With Just One Entry Rule

Kohl's intends to use the net proceeds from the sale of the Notes in a series of transactions resulting in the repayment of borrowings under its revolving credit facility. Kohl's expects to borrow under its revolving credit facility to repay all of its 4.25% notes due 2025 at maturity.

Kohl's Plans $360M Senior Secured Notes Offering Due 2030, Cites Use Of Proceeds For Debt Repayment Strategy

Telsey Advisory Group analyst Dana Telsey maintains FIGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) with a Market Perform and maintains $5 price target.

FIGS

Telsey Advisory Group Maintains Market Perform on FIGS, Maintains $5 Price Target

Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.04 by 380 percent. This is a 230.61 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $81.11 million which missed the analyst consensus estimate of $85.59 million by 5.23 percent. This is a 26.81 percent increase over sales of $63.96 million the same period last year.

NYAX

Nayax Q1 EPS $0.19 Beats $0.04 Estimate, Sales $81.11M Miss $85.59M Estimate

LSEA

Landsea Homes shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results. Also the company announced it entered into a definitive agreement to be acquired by New Home.

PLRZ

Polyrizon Launches Preclinical Studies For Intranasal Benzodiazepines Targeting $3.15B Acute Seizure Market

CNSP

CNS Pharmaceuticals shares are trading higher after the company announced the transfer from Cortice Biosciences of Orphan Drug Designation for TPI 287.

Chardan Capital analyst Rudy Li maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $55 price target.

XENE

Chardan Capital Maintains Buy on Xenon Pharmaceuticals, Maintains $55 Price Target

Needham analyst Chris Pierce reiterates Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) with a Buy and maintains $13 price target.

ACHR

Needham Reiterates Buy on Archer Aviation, Maintains $13 Price Target

ARWR

Arrowhead Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.

"We are excited about the opportunites we're seeing across our business and look forward to driving further revenue growth and value for our shareholders in 2025. We continue to expect full year 2025 GAAP EPS to exceed $2.40 per diluted share, and full year 2025 non-GAAP adjusted EPS to exceed $2.80 per diluted share," Mr. Suzuki concluded.

Guidance

BKTI

CORRECTION: BK Technologies Affirm FY25 GAAP EPS Outlook Of More Than $2.40

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) with a Buy and lowers the price target from $50 to $45.

NGNE

HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $45

MVST

Microvast Holdings shares are trading higher after the company reported better-than-expected Q1 sales results.

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $60 price target.

Comments

F&G Annuities & Life

Intérêt court

F&G Annuities & Life (NYSE:FG) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL